General
Preferred name
CP-547632
Synonyms
OSI-632 ()
CP 547632 ()
VANDETANIB ()
AZD-6474 ()
CP-547632 (hydrochloride) ()
CP 547,632 ()
Cp-547,632 ()
PAN 90806 ()
PAN-90806 ()
CP-632 ()
PAN90806 ()
CP-547632 hydrochloride ()
P&D ID
PD016641
CAS
252003-65-9
252003-71-7
Tags
available
drug candidate
Drug indication
Non-small-cell lung cancer
Age-related macular degeneration
Ovarian cancer
Solid tumour/cancer
Drug Status
investigational
Max Phase
2.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION CP-547632 is a potent inhibitor of VEGFR2 and basic fibroblast growth factor (FGF) receptor kinases . (GtoPdb)
DESCRIPTION CP-547632 is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC50s of 11 nM and 9 nM, respectively. CP-547632 is selective for VEGFR2 and bFGF over EGFR, PDGFR¦Â, and related tyrosine kinases (TKs). CP-547632 has antitumor efficacy[1].
PRICE 101
DESCRIPTION CP-547632 is an orally available and potent, ATP-competitive dual inhibitor of VEGFR-2 and FGF kinase F with IC50s of 11 nM and 9 nM, respectively. CP-547632 is selective, with higher selectivity for VEGFR2 and bFGF than for EGFR, PDGFR?? and related tyrosine kinases (TKs). PDGFR?? and related tyrosine kinases (TKs) CP-547632 has antitumour activity.
DESCRIPTION CP-547632 hydrochloride is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC50s of 11 nM and 9 nM, respectively. CP-547632 hydrochloride is selective for VEGFR2 and bFGF over EGFR, PDGFR¦Â, and related tyrosine kinases (TKs). CP-547632 hydrochloride has antitumor efficacy[1].
DESCRIPTION CP-547632 is as a potent inhibitor of the VEGFR-2 and basic fibroblast growth factor (FGF) kinases (IC50 11 and 9 nM, respectively). It is selective relative to epidermal growth factor receptor, platelet-derived growth factor , and other related TKs. It also inhibits VEGF-stimulated autophosphorylation of VEGFR-2 in a whole cell assay with an IC50 value of 6 nM. After oral administration of CP-547,632 to mice bearing NIH3T3/H-ras tumors, VEGFR-2 phosphorylation in tumors was inhibited in a dose-dependent fashion (EC50 590 ng/ml). CP-547,632 is a well-tolerated, orally-bioavailable inhibitor presently under clinical investigation for the treatment of human malignancies. (BOC Sciences Bioactive Compounds)
DESCRIPTION CP-547632 is an orally available and potent, ATP-competitive dual inhibitor of VEGFR-2 and FGF kinase F with IC50s of 11 nM and 9 nM, respectively. CP-547632 is selective, with higher selectivity for VEGFR2 and bFGF than for EGFR, PDGFRβ and related tyrosine kinases (TKs). PDGFRβ and related tyrosine kinases (TKs) CP-547632 has antitumour activity. (TargetMol Bioactive Compound Library)
Compound Sets
16
Axon Medchem Screening Library
1662
BOC Sciences Bioactive Compounds
cp-547632-cas-252003-65-9-item-88558
Cayman Chemical Bioactives
21773
ChEMBL Drugs
CHEMBL253969
Clinical kinase drugs
Drug Repurposing Hub
DrugBank
DB12962
DrugMAP
DMX054A
Enamine Bioactive Compounds
EBC-764077
Guide to Pharmacology
7881
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL253969
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
CHEMBL253969
MedChem Express Bioactive Compound Library
HY-13302
HY-13302B
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
TargetMol Bioactive Compound Library
T10870L
External IDs
34
Properties
(calculated by RDKit )
Molecular Weight
531.08
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
3
Rotatable Bonds
10
Ring Count
3
Aromatic Ring Count
2
cLogP
3.86
TPSA
109.58
Fraction CSP3
0.45
Chiral centers
0.0
Largest ring
6.0
QED
0.4
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Targets
KDR,FGFR1
Target
VEGFR2
bFGFR
PDGFRβ
BTK
VEGFR2 inhibitor
FGFR
VEGFR
Member status
virtual
MOA
EGFR (HER1| erbB1) Inhibitors
PDGFR Inhibitors
VEGFR-2 (FLK-1/KDR) Inhibitors
Inhibitors of Signal Transduction Pathways
Angiogenesis Inhibitors
kinase inhibitor
Pathway
Angiogenesis
Tyrosine Kinase/Adaptors
Protein Tyrosine Kinase/RTK
Therapeutic Class
Anticancer Agents
Source data